A healthcare company in China headquartered in Shanghai, China focuses on patent licensing, technology acquisition, joint development, etc. The firm seeks new technologies and projects across Greater China, the US, and some European countries.
In the life sciences, the firm is currently looking for innovative therapeutics companies. The firm will focus on assets in five indication areas: oncology, CNS, cardiovascular, metabolic disease and nutritional, and infectious diseases. For the type of modality, the firm is open to companies developing small molecule, biologics, gene therapy and cell therapy. The firm is most interested in products in clinical phase II and phase III stage, but will consider earlier stage companies that show promising technologies.
The firm is interested in privately held life science companies with experienced management teams and innovative technologies.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
A firm that has been actively investing for over 20 years with multiple offices in Europe has over €1 billion in total assets under management and recently closed its first dedicated Health Tech Fund, after successfully investing in the sector from mixed vehicles for more than 20 years. The firm typically invests €1-5 million in early-stage opportunities or up to €10 million in growth-stage opportunities. The firm is currently focused on companies based in Europe.
Within the life science sector, the firm is currently focused on medical technology, diagnostics, life science tools and platforms, and digital health across Europe. The firm is open to opportunities in any indication area and at any phase of development.
The firm is open to investing in companies at early stages with a proof-of-concept, clinically relevant data and/or strong IP positions.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
With RESI SF behind us, we are looking forward to LSN’s first RESI in Europe. Taking place in Vienna, the inaugural RESI Europe will occur on March 25th at the Vienna Marriott Hotel. The application portal is now open for the RESI Europe Innovation Challenge. For RESI San Francisco, LSN received over a hundred applications from startups featuring their new technologies, and we are excited to review your applications for RESI Europe.
Companies can apply through the online portal, with supplementary materials sent to RESI@lifesciencenation.com. The submission deadline is February 20th, 2019.
We will select the top 30 companies as finalists, giving them the opportunity to display a poster featuring their technology in the exhibit hall for the entire day. This will provide these companies with added exposure to the investor attendees. The Innovation Challenge is open to all early-stage companies, whether in therapeutics, diagnostics, medical devices or digital health.
In addition, we will feature 8 of the earliest-stage companies from regional tech hubs, incubators or accelerators in our Pitch Challenge. These companies will pitch in front of a panel of investors, giving them an opportunity to showcase their technology and gain feedback.
We look forward to receiving your application, and we hope to see you at RESI Europe!
RESI’s first Europe event will include three tracks of panel and workshop content aimed at educating entrepreneurs on key topics in life science capital raising. RESI’s panels all feature experienced investors who can provide real-world insights to entrepreneurs and reveal their decision-making process and what catches their eye in a deal.
RESI Europe’s agenda includes our first ever panel on the GreaterEuropean Early-Stage Ecosystem, and a new combined look at Angels and Seed Funds to provide entrepreneurs with actionable insights for their first capital raise. Popular special topic panels return, including AI in Healthcare and Microbiome, and two panels are focused on how to source investors from the Asia region – Asia Therapeutic Investors and Asia Corporates & Strategics. Additionally, RESI Europe features panels on every major life science vertical and on some key investor types such as Family Offices and Corporate Venture Capital. If you’d like to attend these panels live, register for RESI Europe now.
Taiwan has been an important player and a pioneer in the world’s IT industry. Nowadays, through government support, Taiwan is also trying to establish its presence in life science industry, particularly in the Medical Device sector.
At RESI San Francisco during JPM week, LSN and BioMed TW cooperated to launch a new Taiwan Investor panel. The main purpose of this panel is to inform international startups’ on why Taiwan matters. We had the pleasure of inviting 6 panelists from Taiwan – all with a unique background related to Taiwan and working with early-stage innovations – to speak about their work and their perspectives on why international startups should approach Taiwan investors.
Our panelists included:
Michel Chu, General Partner, Acorn Campus Taiwan (Moderator)
Shaoyu Chang, Vice President, FC Capital
IC Jan, Director of Corporate Development, Taiwania Capital
Yi-Yen Chen, Investment Professional, WI Harper Group
Yuh-Geng Tsay, Venture Partner, Vivo Capital
William Tai, Managing Partner, Amed Ventures
Michel Chu, moderator of this panel, addressed the main question: How can Taiwan be a partner to an early-stage startup?
First, Taiwan can be seen as a manufacturing partner – medtech startups can look at Taiwan as a potential OEM/ODM partner. Taiwan is home to many global manufactures in the IT and semiconductor industry. Many of these highly-experienced IT manufacturers in Taiwan are also building medical devices. Thus, working with experienced manufacturers greatly reduces production and quality control risks. The panelists talked about “Design for Manufacturing” as something that is often overlooked by medtech startups – there is often a huge gap from prototype to final product, and the engineering work involved cannot be overlooked. Experienced manufacturers can help to re-engineer the product from a manufacturing perspective. Michel also mentioned that medical device manufacturing is all about quality control, and quality control should be built into the design from day one. Medtech startups should think of Design for Manufacturability (DFM), Design for Inspection (DFI) and Design for Assembly (DFA). In addition, Michel noted that it is becoming increasingly common for manufacturers to also invest in the medtech startups that contract them for their manufacturing needs.
The panel also discussed the fact that Taiwan recently passed legislation to allow people to collect fees from patients for experimental Phase II and Phase III cell therapies on a cost recovery basis. The panelists believe this will be attractive for companies that are planning clinical trials for cell therapies. Since clinical trials for cell therapies cost a fortune, placing some of the study centers in Taiwan may potentially save the company tens of millions of dollars. Also, Taiwan has some of the world’s most renowned hospitals and medical centers with modern facilities including GTP labs. The new regulation has already created a surge in clinical study plans by local and Japanese companies. Overall, the panelists mentioned that even though Taiwan itself is not a very sizable market, it may serve as an excellent strategic partner for global startups.
A transatlantic investor firm headquartered in Europe with additional offices in USA has managed more than $800 million in total assets across six specialized funds. 2 of their funds focus on healthcare service providers based in the Benelux and Germany, and 4 of their funds focus on investing in companies developing therapeutics, medical devices, diagnostics and digital health. The most recent fund closed at $280 million. The firm prefers to invest in clinical stage therapeutics companies and commercial stage diagnostics/medical technology companies. The investment size ranges from $5 million up to $30 million. The firm is seeking to make 2-3 investments over the next 6-9 months, targeting companies based in the U.S. and Europe.
The firm is currently looking for new investment opportunities in Diagnostics, Medical Devices and Digital Health spaces. The firm is very opportunistic in terms of subsectors and indications. The firm does not look at therapeutics or biotech R&D service technologies. For diagnostics and medical devices, the firm is interested in companies with commercial-stage/revenue-generating products, but may also look opportunistically at earlier stage technologies. These may include 510K devices where the FDA clearance is very close and/or where reimbursement is the last hurdle and feel confident in the path to reimbursement. For digital health, the firm looks opportunistically at companies beyond the Series A stage. Historically, the firm was active in medical device companies developing orthotic and prosthetic devices, as well as peripheral vascular applications in cardiovascular diseases.
The firm focuses on investments in private companies and it will consider pre-revenue companies, depending on the opportunity. The firm prefers to invest in companies with experienced and committed management team.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
A large healthcare group that operates 80+ hospitals across Asia, the Middle East and Turkey has an innovation office that acts as a corporate VC arm, which has committed capital of $80 million to invest in the digital health space. The firm typically invests $5-10 million per opportunity, and will invest in companies worldwide that are interested in expanding into Asia.
The firm only invests in the digital health space. The firm is interested in many areas of digital health that are applicable to hospitals, including predictive analytics, genomic data, and AI. The firm does not invest in biopharma or medtech.
The firm will invest globally, and is focused on startups that are interested in expanding into Asia.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
